

In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent

March 14, 2023

ATTORNEYS

Maier, Jeny

Jonathan Gardner

BioPharma Dive

PRACTICE AREAS

Antitrust

Axinn partner Jeny Maier was quoted in the *BioPharma Dive* article, "In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent."

Click [here](#) to access the article.